Ultragenyx Pharmaceutical (RARE) Cash from Operations Growth (1y) (2014 - 2026)
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 100.14% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 56.79% |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | 11.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.01% |
| Mar 31, 2026 | -18.67% |
| Dec 31, 2025 | -25.86% |
| Sep 30, 2025 | -36.09% |
| Jun 30, 2025 | -41.63% |
| Mar 31, 2025 | 12.96% |
| Dec 31, 2024 | 5.69% |
| Sep 30, 2024 | 43.16% |
| Jun 30, 2024 | 33.74% |
| Mar 31, 2024 | -21.59% |
| Dec 31, 2023 | 6.91% |
| Sep 30, 2023 | -23.63% |
| Jun 30, 2023 | -50.36% |
| Mar 31, 2023 | -33.48% |
| Dec 31, 2022 | -66.24% |
| Sep 30, 2022 | -59.84% |
| Jun 30, 2022 | -18.21% |
| Mar 31, 2022 | 26.25% |
| Dec 31, 2021 | 12.98% |
| Sep 30, 2021 | 3.74% |